Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Buckberg cardioplegia
- Development stage
- Phase 4
- Lead developer
- Donald N. Buckberg
- Modality
- Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Administration
- Intracoronary Infusion During Open-heart Surgery Via Antegrade Or Retrograde Delivery[2][4]
01
Overview
Buckberg cardioplegia is a specialized blood-based cardioplegic solution used to induce and maintain cardiac arrest during open-heart surgery. It is designed to protect the myocardium from ischemia-reperfusion injury by providing metabolic substrates, buffering agents, and electrolytes. The solution typically contains potassium chloride (to induce rapid diastolic arrest), magnesium (to reduce calcium influx and potassium efflux), calcium (for membrane integrity), sodium (for extracellular tonicity), dextrose or mannitol (as osmotic agents and metabolic substrates), tromethamine or bicarbonate (as buffers for pH maintenance), aspartate and glutamate (amino acids that replenish Krebs cycle intermediates under anaerobic conditions). The unique feature of the Buckberg protocol is its use of both cold induction/maintenance doses followed by a warm "hot shot" reperfusion dose at the end of ischemia. This approach aims to optimize myocardial protection during periods of aortic cross-clamping in cardiac surgery[1][2][4].
- Brand names
- Buckberg cardioplegia
- Other names
- Buckberg solutionBuckberg停搏液
02
Targets
LTCC (Voltage-gated calcium channel (L-type))Kir (Inward-rectifier potassium channels)NaV (Voltage-gated sodium channels)KCNQ1 (Potassium voltage-gated channel subfamily KQT member 1)
Beyond the preview
Go deeper on Buckberg cardioplegia.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Buckberg cardioplegia.